Company Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.
Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009.
Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 2006 |
| IPO Date | Nov 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 74 |
| CEO | Sean Bohen |
Contact Details
Address: 780 Brannan Street San Francisco, California 94103 United States | |
| Phone | 415 651 3316 |
| Website | olema.com |
Stock Details
| Ticker Symbol | OLMA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001750284 |
| CUSIP Number | 68062P106 |
| ISIN Number | US68062P1066 |
| Employer ID | 30-0409740 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sean P. Bohen M.D., Ph.D. | President, Chief Executive Officer and Director |
| Shane William Charles Kovacs M.B.A. | Chief Operating and Financial Officer |
| Dr. Naseem Zojwalla M.D. | Chief Medical Officer |
| Courtney O'Konek | Vice President of Corporate Communications |
| Julie Dexter | Senior Vice President and Head of People |
| Dr. David C. Myles Ph.D. | Chief Discovery and Non-Clinical Development Officer |
| Sasha Austin CPA | Vice President of Finance and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Sep 27, 2024 | 8-K | Current Report |
| Aug 6, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |
| Jul 30, 2024 | 144 | Filing |
| Jul 29, 2024 | 144 | Filing |
| Jul 11, 2024 | 144 | Filing |